Results 31 to 40 of about 22,026 (263)

Dipeptidyl-Peptidase IV inhibitors and glycemic control in type 2 Diabetes Mellitus

Journal of College of Medical Sciences-Nepal, 2016
Background & Objectives: Type 2 diabetes mellitus (T2DM) is a progressive disease, characterized by insulin resistance, impaired glucose-induced insulin secretion, inappropriately elevated glucagon concentrations, and hyperglycemia.
Lokendra Bahadur Sapkota, Sangita Thapa
doaj   +1 more source

Dipeptidyl peptidase IV inhibitors derived from a mangrove flora Rhizophora mucronata: An in silico approach

Bangladesh Journal of Pharmacology, 2012
Dipeptidyl peptidase IV (DPP IV) is responsible for conversion of glucose tolerance (GLP-1), into inactive form. The inhibition of DPP IV would be beneficial in the treatment of diabetes mellitus.
Selvaraj Gurudeeban, Kaliyamurthi Satyavani, Thirugnanasambandam Ramanathan, Palanisamy Ravikumar   +3 more
doaj   +1 more source

Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study

Pharmaceuticals, 2020
Five novel peptides (LPLF, WLQL, LPSW, VPGLAL, and LVGLPL) bearing dipeptidyl peptidase IV (DPP-IV) inhibitory activities were identified from the gastrointestinal enzymatic hydrolysate of soft-shelled turtle yolk (SSTY) proteins.
Nhung Thi Phuong Nong, Yu-Kuo Chen, Wen-Ling Shih, Jue-Liang Hsu   +3 more
doaj   +1 more source

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. [PDF]

PLoS ONE, 2012
BACKGROUND: Natural extracts play an important role in traditional medicines for the treatment of diabetes mellitus and are also an essential resource for new drug discovery.
Laura Guasch, Esther Sala, María José Ojeda, Cristina Valls, Cinta Bladé, Miquel Mulero, Mayte Blay, Anna Ardévol, Santiago Garcia-Vallvé, Gerard Pujadas   +9 more
doaj   +1 more source

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

Pharmaceuticals, 2021
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally.
Praveen P. N. Rao, Amy Trinh Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, Ahmed A. Hefny   +6 more
doaj   +1 more source

DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses

Molecules, 2018
Dipeptidyl peptidase IV (DPP-IV), a new target for the treatment of type 2 diabetes mellitus, degrades incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide. DPP-IV inhibitors shorten the inactivation of GLP-1,
Bo-Ram Kim, Hyo Young Kim, Inhee Choi, Jin-Baek Kim, Chang Hyun Jin, Ah-Reum Han   +5 more
doaj   +1 more source

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes [PDF]

, 2017
This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record.The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management ...
Paldanius, PM, Strain, WD
core   +1 more source

COVID-19 and chronological aging : senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? [PDF]

, 2020
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family.
Auwerx, Blagosklonny, Blagosklonny, Blagosklonny, Colasurdo, Colson, Diaz-Quijano, Du, Erusalimsky, Gerontol, Gorospe, Hoffmann, Häkkinen, Jang, Li, Lisanti, Lisanti, Lu, Masternak, Munster, Musso, Nowakowski, Porter, Subbarao, Subbarao, Tanga, Tremblay, Wilce, Yaron, Yusof, Zhang   +30 more
core   +2 more sources

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes [PDF]

, 2017
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients.
Fernandes, Rosa, Lemos, Edite Teixeira de, Mega, Cristina, Reis, Flávio   +3 more
core   +3 more sources

Synthetic Approaches to Novel DPP-IV Inhibitors—A Literature Review

Molecules
Dipeptidyl peptidase IV (DPP-IV) is a serine protease whose inhibition has been an object of considerable interest in the context of developing novel treatments for type 2 diabetes mellitus.
Valentin Petrov, Teodora Aleksandrova, Aleksandar Pashev   +2 more
doaj   +1 more source